<DOC>
	<DOC>NCT01022996</DOC>
	<brief_summary>This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment.</brief_summary>
	<brief_title>Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patients with a history of classical Hodgkin's lymphoma that has progressed after highdose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine or vinorelbine or vinblastinebased treatment Patients with at least one site of measurable disease measuring ≥ 2.0cm confirmed by PET and CT Scan (or MRI) Patients with adequate bone marrow, liver and renal function (confirmed by laboratory values) Patients with fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN Previous treatment with mTOR inhibitors Prior allogeneic stem cell transplant Chemotherapy, monoclonal antibody therapy, major surgery or treatment with other investigational drugs within 4 weeks of starting study treatment Another malignancy within 3 years of study entry (except adequately treated nonmelanoma skin cancer and carcinoma in situ of the cervix) Severe and/or uncontrolled medical conditions that could affect participation in this study Female patients who are pregnant or breastfeeding; patients who are not willing to use adequate birth control during the study and for 8 weeks after the last study treatment Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hodgkin's Lymphoma</keyword>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Hodgkin's Disease</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Neoplasms by Histological type</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Hemic and Lymphatic Diseases</keyword>
	<keyword>Recurrent Lymphoma</keyword>
	<keyword>Refractory Lymphoma</keyword>
	<keyword>Relapsed Lymphoma</keyword>
	<keyword>Classical Hodgkin Lymphoma</keyword>
	<keyword>Classical Hodgkin's Disease</keyword>
	<keyword>Nodular sclerosing Hodgkin Lymphoma</keyword>
	<keyword>Mixed-cellularity Hodgkin Lymphoma</keyword>
	<keyword>Lymphocyte-rich Hodgkin Lymphoma</keyword>
	<keyword>Lymphocyte depleted Hodgkin Lymphoma</keyword>
</DOC>